The expanding clinical use of C-peptide radioimmunoassay

Marc Rendell

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

C-peptide levels are in many ways a better measure of endogenous insulin secretion than peripheral insulin levels. C-peptide may be measured in either blood or urine. Perhaps the major advantage of measuring C-peptide levels is the ability to readily distinguish endogenous insulin levels in the presence of exogenous administration of insulin. Early C-peptide immunoassays were troubled by lack of sensitivity. This problem has now been overcome, and it is possible to measure C-peptide values down to extremely low levels. The clinical indications for C-peptide measurement include diagnosis of insulinoma and differentiation from factitious hypoglycemia, follow-up of pancreatectomy and evaluation of viability of islet cell transplants. Recently these indications have been dramatically expanded to permit evaluation of insulin dependence in maturity onset diabetes mellitus.

Original languageEnglish
Pages (from-to)105-113
Number of pages9
JournalActa Diabetologica Latina
Volume20
Issue number2
DOIs
StatePublished - Jun 1983
Externally publishedYes

Fingerprint

C-Peptide
Radioimmunoassay
Insulin
Insulinoma
Pancreatectomy
Islets of Langerhans
Immunoassay
Hypoglycemia
Type 2 Diabetes Mellitus
Urine
Transplants

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

The expanding clinical use of C-peptide radioimmunoassay. / Rendell, Marc.

In: Acta Diabetologica Latina, Vol. 20, No. 2, 06.1983, p. 105-113.

Research output: Contribution to journalReview article

Rendell, Marc. / The expanding clinical use of C-peptide radioimmunoassay. In: Acta Diabetologica Latina. 1983 ; Vol. 20, No. 2. pp. 105-113.
@article{784cb0a2c6c542baaf3b83366f4a2759,
title = "The expanding clinical use of C-peptide radioimmunoassay",
abstract = "C-peptide levels are in many ways a better measure of endogenous insulin secretion than peripheral insulin levels. C-peptide may be measured in either blood or urine. Perhaps the major advantage of measuring C-peptide levels is the ability to readily distinguish endogenous insulin levels in the presence of exogenous administration of insulin. Early C-peptide immunoassays were troubled by lack of sensitivity. This problem has now been overcome, and it is possible to measure C-peptide values down to extremely low levels. The clinical indications for C-peptide measurement include diagnosis of insulinoma and differentiation from factitious hypoglycemia, follow-up of pancreatectomy and evaluation of viability of islet cell transplants. Recently these indications have been dramatically expanded to permit evaluation of insulin dependence in maturity onset diabetes mellitus.",
author = "Marc Rendell",
year = "1983",
month = "6",
doi = "10.1007/BF02624911",
language = "English",
volume = "20",
pages = "105--113",
journal = "Acta Diabetologica",
issn = "0940-5429",
publisher = "Casa Editrice II Ponte",
number = "2",

}

TY - JOUR

T1 - The expanding clinical use of C-peptide radioimmunoassay

AU - Rendell, Marc

PY - 1983/6

Y1 - 1983/6

N2 - C-peptide levels are in many ways a better measure of endogenous insulin secretion than peripheral insulin levels. C-peptide may be measured in either blood or urine. Perhaps the major advantage of measuring C-peptide levels is the ability to readily distinguish endogenous insulin levels in the presence of exogenous administration of insulin. Early C-peptide immunoassays were troubled by lack of sensitivity. This problem has now been overcome, and it is possible to measure C-peptide values down to extremely low levels. The clinical indications for C-peptide measurement include diagnosis of insulinoma and differentiation from factitious hypoglycemia, follow-up of pancreatectomy and evaluation of viability of islet cell transplants. Recently these indications have been dramatically expanded to permit evaluation of insulin dependence in maturity onset diabetes mellitus.

AB - C-peptide levels are in many ways a better measure of endogenous insulin secretion than peripheral insulin levels. C-peptide may be measured in either blood or urine. Perhaps the major advantage of measuring C-peptide levels is the ability to readily distinguish endogenous insulin levels in the presence of exogenous administration of insulin. Early C-peptide immunoassays were troubled by lack of sensitivity. This problem has now been overcome, and it is possible to measure C-peptide values down to extremely low levels. The clinical indications for C-peptide measurement include diagnosis of insulinoma and differentiation from factitious hypoglycemia, follow-up of pancreatectomy and evaluation of viability of islet cell transplants. Recently these indications have been dramatically expanded to permit evaluation of insulin dependence in maturity onset diabetes mellitus.

UR - http://www.scopus.com/inward/record.url?scp=0020743754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020743754&partnerID=8YFLogxK

U2 - 10.1007/BF02624911

DO - 10.1007/BF02624911

M3 - Review article

C2 - 6410638

AN - SCOPUS:0020743754

VL - 20

SP - 105

EP - 113

JO - Acta Diabetologica

JF - Acta Diabetologica

SN - 0940-5429

IS - 2

ER -